about
Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infectionsPlasmodium knowlesi malaria in humans is widely distributed and potentially life threateningLoss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargementThe IGSF1 deficiency syndrome: characteristics of male and female patientsClinical and Laboratory Features of HumanPlasmodium knowlesiInfectionRationale, design and methods for a community-based study of clustering and cumulative effects of chronic disease processes and their effects on ageing: the Busselton healthy ageing study.Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivitySubacute sclerosing panencephalitis in papua new guinean children: the cost of continuing inadequate measles vaccine coverage.Effects of a high-fat meal on the relative oral bioavailability of piperaquineParameterization of high magnetic field gradient fractionation columns for applications with Plasmodium falciparum infected human erythrocytesThe diagonal ear lobe crease (Frank's sign) is not associated with coronary artery disease or retinopathy in type 2 diabetes: the Fremantle Diabetes Study.A sub-microscopic gametocyte reservoir can sustain malaria transmission.Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria.Mathematical modeling of malaria infection with innate and adaptive immunity in individuals and agent-based communities.Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.Piperaquine: a resurgent antimalarial drug.Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New GuineaPlasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New GuineaViral pathogens in children hospitalized with features of central nervous system infection in a malaria-endemic region of Papua New Guinea.Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugsRole of P glycoprotein in absorption of novel antimalarial drugs.Increasing chloramphenicol resistance in Streptococcus pneumoniae isolates from Papua New Guinean children with acute bacterial meningitis.Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria.Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetesPharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.Common infections in diabetes: pathogenesis, management and relationship to glycaemic control.Prospects for the treatment of drug-resistant malaria parasites.A comparison of the sensitivities of detection of Plasmodium falciparum gametocytes by magnetic fractionation, thick blood film microscopy, and RT-PCR.Ethnic diversity in type 2 diabetes.Prevalence and implications of cerebrospinal fluid leukocytosis in Papua New Guinean children hospitalized with severe malariaConfirming cerebral malaria deaths in resource-limited settings.
P50
Q24617466-27739A12-1FE5-4784-9AE9-932796BBABB1Q24651907-D772995E-F065-4A25-A513-4D475B809CD2Q28279078-35178C70-0AA6-4A89-BD89-A1E42070AEB2Q28300032-73342566-51A0-4DB1-A1E0-B51784A10D0BQ29999621-E2342D0C-15C2-4606-9CF8-F3A0234EC450Q30446141-FC6F1068-EE80-4338-8419-234ECEB238F8Q33305306-141F23A4-823E-430E-B097-F3AC9162B82BQ33562855-E86C7295-3F66-4952-892D-6771C0088D8FQ33796521-212725E1-105C-4784-B70A-5308B0F2A7F8Q33836733-F3BAC4F2-4788-496A-9C48-18ADA7184936Q33878921-EDC9E7C1-1530-48ED-8BD1-772486D18D2FQ33927383-6E51DD15-D8DA-41D2-995B-D43589D6CD42Q33939379-9E919B47-3CCB-41C5-AA0B-33C8F18747EAQ33981168-EBF27394-8B58-4FAA-A6D5-A824B2C6BEE2Q34217648-61079BD2-A59F-488F-8E55-EBAF8CBDEDC4Q34299178-3F2823A3-6332-4090-9F2B-77EBCC103583Q34347059-A03EEEBC-FBFC-43B4-8752-E4F823331221Q34378146-04192F8D-DCD2-4AD6-832D-753A08B6E0A6Q34509744-67C2B980-AE0F-498D-8F80-571331F70DB3Q34596548-5E08EEE0-9606-46BF-B201-F0AF60507926Q34659475-2FCE7473-1238-4542-B850-7947D91F71F9Q34719976-6DD165D1-DF13-4520-84BC-6884B2DA8E22Q34737444-DFEF88EE-37F4-452B-B575-43AB8FCF8A61Q34973806-21607586-A3A5-4CB3-87CB-FDE4377C99F1Q35091572-DA07E917-D4D0-403F-9DD1-AAB21B212E37Q35191559-BEE3C07E-CC01-41EC-82D4-F10081438064Q35206338-E7B487EA-11D3-4C04-B1E1-6D8A89E2D056Q35363936-9795E774-E55A-4CE7-B951-6699C92F4A33Q35607695-0A8FBCAC-03E0-41AB-88CE-FE4E12486BD5Q35607781-C2EDDC54-5BA0-4566-B974-6AD5662B06C5Q35802096-80D290D4-25BD-4362-99BB-D641BE2FD24AQ35898200-B8A093BD-6700-4E77-BBA3-E83C28933B41Q36055097-EC008B8E-3990-4960-8E8A-5ED202D4B433Q36422652-95A481EA-F2CD-45EF-B3A5-6CFA979D15EFQ36589117-F04B945C-B439-4E8C-BBA7-95D430B63324Q36895758-D02A0044-0C46-4F2E-B538-5818286E3650Q37209514-010C6D65-B707-4833-BB49-5F6D4667E9D8Q37248804-A68AE61C-922A-4433-92AF-8149CEAF8CA4Q37287650-A7D21471-4D46-461E-A255-DA394920193DQ37572861-75C60171-4C26-4CBB-B1CE-77F84D8F2699
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Timothy M Davis
@ast
Timothy M Davis
@en
Timothy M Davis
@es
Timothy M Davis
@nl
type
label
Timothy M Davis
@ast
Timothy M Davis
@en
Timothy M Davis
@es
Timothy M Davis
@nl
prefLabel
Timothy M Davis
@ast
Timothy M Davis
@en
Timothy M Davis
@es
Timothy M Davis
@nl
P106
P31
P496
0000-0003-0749-7411